ESR1 and T-cell acute lymphoblastic leukemia: JQ1 has also been found to have synergistic effects on the inhibition of tumor cell proliferation when combined with fulvestrant, an estrogen receptor antagonist, in breast cancer [29], γ-secretase inhibitors in T cell acute lymphoblastic leukemia [30] and histone deacetylase inhibitors in murine lymphoma [31].